研究结果:重组人促红素可预防血肌酐及血尿素氮升高。
组别
1 2 3 4 P值
治疗前 21.80±0.49 21.75±0.43 21.80±0.49 21.78±0.55
n.s
各实验组血清BUN及Cr水平 BUN (mg/dl)
Cr (mg/dl)
治疗后
∆
治疗前
治疗后
∆
22.60±0.65
0.8±0.72
• 研究结论
– 腹膜透析患者贫血治疗仍不充分,Hb达标率较低 – 本研究中EPO用量与国外报道数据相比偏低,特别是重度贫血组患者,每
周用量未达到10000U;目前透析患者贫血治疗达标率低与EPO剂量不足 有关,特别是中重度贫血患者 – 肾性贫血治疗应重视EPO的早期、足量应用
林攀等.上海市透析患者贫血治疗现况调查.肾脏病与透析肾移植杂志.2011.20(4):332-337
大气氧分压↓ 组织血流↓
血红蛋白氧亲和力↑ 组织耗氧↑
– 血液稀释、红细胞寿命缩短、溶血尿毒症综合征、出血倾向、营养缺乏
1. 姚泰等.生理学.人民卫生出版社.2010:83 2. 张之南.血液病学.人民卫生出版社.2011:1449-1450
• 炎症
– 通过多种途径抑制EPO的活性,影响红细胞生成 – 加强外周红细胞的清除 – 炎症状态时使铁的利用障碍,导致生理性铁缺乏1
抗凋亡 作用2
抗氧化 作用6,7
EPO对肾 脏保护机
制
抗炎作 用3
促血管 生成作
用5
提高机 体免疫 功能4
1. Nasri H.Renal Cell Protection of Erythropoietin beyond Correcting The Anemia in Chronic Kidney Disease Patients.Cell J. 2014 Winter;15(4):378-80. 2. Sharpies EJ,Patel N,Brown P,et al.Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia reperfusion.J AmSoc Nephrol,2004,15:2115-2124 3. Choi DE.Jeong JY,I im BJ,et al.Pretreatment with darbepoetin attenuates renal injury in a rat model of cisplatin-induced nephro-toxicity.Korean j Intern Med,20()9,24:238-246. 4. Schaefer RM,Paezek L,Berthold G,et al.Improved immunoglobulin production in dialysis patients treated with recombinant erythropoietin.Int J Artif Organs,1 992,15:204-208. 5. Jaquet K,Krause K,Tawakol-Khodai M,et al.Erythropoietin and VEGF exhibit equal angiogenic potential.Mieovasc Res, 2002,64:326 333. 6. Ohashi R,Shimizu A,Masuda Y,et al.Per(tubular capillary regression during the progression of experimental obstructive nephropathy.J Am Soc Nephrol,2002,13:1795 1805. 7. Sun D,Feng J,Dai C,et al.Role of pertubular capillary loss and hypoxia in progressive tubulointerstitial fibrosis in a rat model of aristolochic acid nephropathy.Am J Nephrol,2006,26:363-371.